Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

155.78 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Wall Street’s Favorite Long-Term Stocks? 3 Names That Could Make You Filthy Rich
Wall Street's favorite long-term stocks JNJ, KO, and CAT offer a blend of dividend reliability, sector diversity, and strong market presence 
Via InvestorPlace
Johnson & Johnson's Abiomed Unit Recalls Instructions For Some Impella Blood Pumps Due To Cutting Risks
Johnson & Johnson's Abiomed's Impella Left Sided Blood Pumps, used in high-risk heart procedures, recalled due to potential perforation risk. FDA reports 129 serious injuries, 49 deaths. Learn more... 
Via Benzinga
Topics Death Product Recall
Exposures Death Legal Product Safety
Dear 3M Stock Fans, Mark Your Calendars for April 1
Investors are split on MMM stock ahead of 3M's long-awaited healthcare spinoff, Solventum, launching April 1. 
Via InvestorPlace
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart... 
Via Benzinga
Should You Buy 3M Before April 1?
A looming stock spinoff should give investors a reason to pause. 
Via The Motley Fool
Bev Jennings selected as VIP Speaker at Global Women Thrive Summit 2024
The presentation is virtual and live in-person as part of a collaboration with the WBENC Amplify Conference in Denver, COJACKSONVILLE, Fla. & DENVER - March 16, 2024 - PRLog -- Bev Jennings, a VIP... 
Via PRLog
Topics Supply Chain
Exposures Supply Chain
Analyzing NYSE:JNJ's Dividend Potential.
Why JOHNSON & JOHNSON (NYSE:JNJ) qualifies as a good dividend investing stock. 
Via Chartmill
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
Via Benzinga
Jim Cramer Reveals Nvidia's Non-Tech Partners That Can Be Potential Market Winner: 'Best Opportunities'
CNBC host Jim Cramer has spotlighted several lesser-known partners of Nvidia that could potentially benefit from the company's advanced artificial intelligence technology. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Defensive Stocks to Build a Moat Around Your Portfolio
Although the market seems to continuously be on the rise, some concerning data suggests investors should consider defensive stocks. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Next Great Biotech Boom Has Arrived
EQNX::TICKER_START (NYSE:JNJ),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:ATAI),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
Via Benzinga
Exposures Product Safety
Guardians of Your Golden Years: 7 Stocks Every Retiree Needs to Own
Investing in your golden years is about choosing stocks for retirees that are low-risk, offer passive income and steadily grow. 
Via InvestorPlace
Meet the "Magnificent Seven" Stock That Pays More Dividends Than Any Other U.S.-Based Company
Microsoft is the complete package. 
Via The Motley Fool
Johnson & Johnson Stock Is Great. Here's Why You Shouldn't Buy It.
Johnson & Johnson's days of being a top healthcare stock could be long gone. 
Via The Motley Fool
The Taxman Cometh: 3 Stocks to Soften the Blow and Grow Your Dough
Dive into tax season stocks, featuring dividend-rich JNJ and EQIX, plus growth-focused TSLA, for a smarter tax season strategy. 
Via InvestorPlace
Why Abbott's Formula-Related Sell-Off Could Be A Buying Opportunity, Says Analyst
Fellow infant formula maker Reckitt Benckiser was ordered to pay $60 million to a mother whose baby died after eating Enfamil. 
Via Investor's Business Daily
Topics Death
Exposures Death
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
German Conglomerate Bayer Goes Johnson & Johnson Way To Tackle Its Cancer Related Lawsuits
Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the controversial tactic and its potential implications. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Glyphosate Legal
The 3 Most Undervalued Healthcare Stocks to Buy in March 2024
Wager on these promising undervalued healthcare stocks, catering to investors aiming to leverage growth within the dynamic healthcare space. 
Via InvestorPlace
Top Stock Reports For UnitedHealth, Johnson & Johnson & Oracle
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc. (UNH), Johnson & Johnson (JNJ) and Oracle Corp. (ORCL). 
Via Talk Markets
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
Exposures Product Safety
3 No-Brainer Stocks to Buy With $300 Right Now
A reasonably modest amount of money can go a long way when it's put to work in historically cheap, industry-leading businesses. 
Via The Motley Fool
7 High-Quality Blue-Chip Stocks to Buy if You’re Looking for Stability
With the market facing a possible rotation out of hot tech names, these stable blue-chip stocks may offer investors confidence. 
Via InvestorPlace
Golden Cross Alert: Johnson & Johnson Shines With Ambrx Deal, Bullish Technical Signal
Johnson & Johnson stock down 1.22% in 6 months, up 5.57% in a year, and 3% YTD. Recent acquisition of Ambrx Biopharma boosts stock. Golden Cross signals trend reversal. 
Via Benzinga
3 Must-Have Dividend Kings for a Steady Income Stream
Discover the dividend kings with constant growth, dominating pharmaceuticals, household products and biotechnology industries. 
Via InvestorPlace
2 High-Yield Dow Jones Dividend Stocks to Buy Now and Hold Forever
These industry leaders boast advantages that could expand their bottom lines for decades. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
From Johnson & Johnson
Via Business Wire
The Dow’s Best Friends: 3 ‘Dogs’ Ready to Fetch Huge Returns
The Dogs of the Dow strategy is one of the best yearly strategies investors should use to make some good money. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.